MannKind Corporation held an investor call on February 3, 2016 in which CEO Matt Pfeffer said that the company might co-promote Afrezza inhaled insulin with a partner or partners after Sanofi returns the rights, but that MannKind would retain full rights to the product and will market Afrezza itself after the transition, which is anticipated to occur around April 5, 2016.
$MNKD CEO: “MNKD will retain full rights & ownership of Afrezza, at most, co-promoting Afrezza with additional partner(s).” #MNKD2316
— MannKind (@MannKindCorp) February 3, 2016
The company also said that it is looking to hire a VP of sales/marketing and that when looking to overseas markets, it would prioritize international regions where it can file for approval based solely on the US NDA without conducting additional trials.
Pfeffer reiterated that MannKind’s new development partner for other Technosphere based inhalation products, Receptor Life Sciences, is an independent company.
$MNKD CEO: “RLS is indep co, with collaboration & licensing agreement with MNKD. MNKD retains ownership of Technosphere IP.” #MNKD2316
— MannKind (@MannKindCorp) February 3, 2016
He identified treprostinil, palonosetron, and epinephrine as the top candidates in MannKind’s pipeline and emphasized the company’s IP, including 918 patents, as a key asset.
$MNKD CMO: “MNKD has 918 patents encompassing powders, devices and manufacturing technologies.” # MNKD2316
— MannKind (@MannKindCorp) February 3, 2016
According to the announcement for the call, “A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 41729996#. A replay will also be available on MannKind’s website for 14 days.”
